Physician profile
Jorge D Castaneda
NPI 1457332074
$8,127.19
in general payments reported to CMS, 2019-2025
32 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $1,037 · 2021: $1,407 · 2022: $1,114 · 2023: $1,249 · 2024: $1,015 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,580.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,190.73 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,641.42 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $595.17 | 2021-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $499.03 | 2019-2025 | Ocaliva |
| Ardelyx, INC. | $419.89 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $333.52 | 2020-2025 | Talicia, Movantik, Aemcolo |
| Braintree Laboratories, INC. | $268.11 | 2019-2025 | Sutab, Suflave |
| Lilly USA, LLC | $261.95 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $239.91 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $208.20 | 2019-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $201.10 | 2019-2025 | Eohilia, Gattex |
| Madrigal Pharmaceuticals | $157.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Allergan, INC. | $151.48 | 2019-2020 | |
| Haemonetics Corporation | $130.13 | 2023 | Teg6s Hemostasis System |
| Vivus LLC | $107.85 | 2021-2025 | Qsymia, Pancreaze |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $79.40 | 2024-2025 | Iqirvo |
| Pfizer INC. | $65.39 | 2025 | |
| Alfasigma USA, INC. | $64.09 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $63.13 | 2021-2023 | |
| Qol Medical, LLC | $58.20 | 2021-2025 | Sucraid |
| Aimmune Therapeutics, INC. | $56.47 | 2024 | |
| Celgene Corporation | $55.50 | 2021-2022 | |
| Romark Laboratories, Lc | $48.43 | 2019 | |
| Gilead Sciences, INC. | $46.87 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $41.68 | 2019 | |
| Merck Sharp & Dohme LLC | $34.52 | 2021-2022 | |
| Medtronic, INC. | $32.63 | 2025 | Endurant Iis |
| Daiichi Sankyo INC. | $23.40 | 2020 | |
| Exact Sciences Corporation | $20.97 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $19.12 | 2025 | Wegovy |
| Organon LLC | $11.14 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Castaneda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.